<DOC>
	<DOCNO>NCT02468193</DOCNO>
	<brief_summary>The study aim investigate efficacy safety Osilodrostat patient Cushing 's syndrome due cause Cushing 's disease Japan .</brief_summary>
	<brief_title>Study Efficacy Safety Osilodrostat Cushing 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Cardiac Complexes , Premature</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<mesh_term>Adrenocortical Adenoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>ACTH Syndrome , Ectopic</mesh_term>
	<criteria>Patients confirm Cushing 's syndrome [ i.e . ectopic corticotropin syndrome , adrenal adenoma , adrenal carcinoma , ACTHIndependent Macronodular Adrenal Hyperplasia ( AIMAH ) , Primary Pigmented Nodular Adrenal Dysplasia ( PPNAD ) ] For patient medical treatment hypercortisolism due Cushing 's syndrome , washout period must complete prior baseline efficacy assessment Patients Cushing 's disease History hypersensitivity osilodrostat drug similar chemical class History malignancy organ system , treat untreated , within past 5 year Patients receive treatment within 4 week â‰¤5 x halflife agent ( whichever longer ) first dose osilodrostat Patients risk factor QTc prolongation Torsade de Pointes Other protocol define Inclusion/Exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cushing 's syndrome</keyword>
	<keyword>osilodrostat</keyword>
	<keyword>LCI699</keyword>
	<keyword>ectopic corticotropin syndrome</keyword>
	<keyword>adrenal adenoma</keyword>
	<keyword>adrenal carcinoma</keyword>
	<keyword>ACTH-Independent Macronodular Adrenal Hyperplasia</keyword>
	<keyword>AIMAH</keyword>
	<keyword>Primary Pigmented Nodular Adrenal Dysplasia</keyword>
	<keyword>PPNAD</keyword>
</DOC>